| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b8cda447db0ecc895e8b1eb7db419a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4397a7101a26a73eb6592cfc7cdb553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d41a7d9056e21e61e70994bb5d7ded8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_396ebf23018b0c0ecf1fb4ae221150e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d234dd8798c2a26c3eaac363669f57e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_935125d633316ffec730c56d4e557694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_759ff62f34b17396a1311fa600073615 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N1-30 |
| filingDate |
2015-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05adbca335ed0781aa535e7ee917be39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1662b9b1faec4cd233333697d6dbe680
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cea3d837008421c38947deaa904ce34c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccce2d3f4334b6d0ba3382df32436ca5 |
| publicationDate |
2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9645152-B2 |
| titleOfInvention |
Methods for predicting the survival time of a patient suffering from a solid cancer |
| abstract |
The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis. |
| priorityDate |
2012-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |